Wenfeng Fang

机构：Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China · ORCID：0000-0002-6440-8246

发表论文 435 篇 · 总被引 10366 次 · h-index 49

代表论文

• EGFR activation disrupts immunotherapy response via SHP2-mediated suppression of tumor-intrinsic response to IFN-γ (2026 · Journal of Clinical Investigation · 被引 3)
• The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer (2026 · Cancer Discovery · 被引 2)
• Efficacy and Safety of Atezolizumab Plus Bevacizumab in Patients With Advanced NSCLC Who Received Pretreatment With EGFR ‐ TKIs ( ML41256 ): A Multicenter, Prospective, Single‐Arm, Phase 2 Trial (2025 · Cancer Medicine · 被引 1)
• Supplementary Figure S2 from The Oncogenic <i>EGFR–SHC1</i> Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer (2026)
• Supplementary Figure S5 from The Oncogenic <i>EGFR–SHC1</i> Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer (2026)
• Supplementary Table S4 from The Oncogenic <i>EGFR–SHC1</i> Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer (2026)